Is Boundless Bio, Inc. (BOLD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 188.3% / 30% | 601.3% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 188.3% / 33% | 601.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 23.1% / 33% | 73.7% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 188.3% / 33% | 601.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 23.1% / 33% | 73.7% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -46.7% | |
| Return on Assets (ROA) | -21.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$47M |
| Free Cash Flow | -$47M |
| Total Debt | $49M |
| Debt-to-Equity | 49.7 |
| Current Ratio | 8.7 |
| Total Assets | $157M |
Price & Trading
| Last Close | $1.11 |
| 50-Day MA | $1.16 |
| 200-Day MA | $1.18 |
| Avg Volume | 113K |
|
52-Week Range
$0.96
| |
About Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Boundless Bio, Inc. (BOLD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Boundless Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Boundless Bio, Inc.'s debt ratio?
Boundless Bio, Inc.'s debt ratio is 188.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 23.1%.
What are Boundless Bio, Inc.'s key financial metrics?
Boundless Bio, Inc. has a market capitalization of $25M. Return on equity stands at -46.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.